Scientists discovered a genetic marker that predicts before MS therapy whether glatiramer acetate or interferon is likely to ...

Columnist Leigh Anne Nelson once chalked up new neurological symptoms to her MS, but she now realizes that assumption could ...

People who develop MS begin using healthcare services more frequently up to 15 years before their MS symptoms first appear.

Columnist Desiree Lama has had to find some self-care strategies for managing her MS while also staying atop her work as a ...

Enrollment is complete for a Phase 2 trial testing Zenas Biopharma's obexelimab in relapsing MS, with results expected later ...

The experimental CAR T-cell therapy treatment was given as part of a clinical trial that's enrolling adults with progressive ...

Better physical performance is associated with higher cognitive function in people with MS, particularly in those with ...

Beneficiaries of plans that covered fewer than the median number of DMTs in the past year were more likely to have a relapse, ...

Quantum signed a manufacturing agreement for the production of Lucid-MS as it prepares for a Phase 2 trial of the ...

Lucid-MS, Quantum Biopharma's oral multiple sclerosis therapy candidate, was not toxic and had no side effects in healthy ...

A study found neurofilament light chain at high levels in the blood and CSF of MS patients, suggesting its potential as a ...

Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow ...